Checkpoint Therapeutics Launches Phase 3 Trial of Lung Cancer Drug

9:46AM ET 12/08/2021 MT Newswires
Checkpoint Therapeutics (CKPT) said Wednesday it launched a phase 3 trial of cosibelimab combined with chemotherapy in patients with first-line non-squamous non-small cell lung cancer.

The primary endpoint for the trial is overall survival and the study is designed to support full regulatory approvals around the world, according to the company.

Price: 2.96, Change: +0.04, Percent Change: +1.37